SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 31, 1999.
BioTime, Inc.
(Exact name of registrant as specified in its charter)
California 1-12830 94-3127919
(State or other (Commission File Number) (IRS Employer
jurisdiction of incorporation) Identification No.)
935 Pardee Street
Berkeley, California 94710
(Address of principal executive offices)
(510) 845-9535
(Registrant's telephone number, including area code)
<PAGE>
Statements made in this Report that are not historical facts may
constitute forward-looking statements that are subject to risks and
uncertainties that could cause actual results to differ materially from those
discussed. Such risks and uncertainties include but are not limited to BioTime's
ability to obtain foreign regulatory approval to market Hextend; competition
from products manufactured and sold or being developed by other companies; the
price of and demand for Hextend; BioTime's ability to negotiate favorable
foreign licensing or other manufacturing and marketing agreements for Hextend;
the availability of ingredients used in Hextend; and the availability of
reimbursement for the cost of Hextend (and related treatment) from government
health administration authorities, private health coverage insurers and other
organizations. These and other risk factors are discussed in BioTime's Annual
Report on Form 10-K filed with the Securities and Exchange Commission.
Item 5. Other Events.
On March 31, 1999, BioTime received approval from the United States
Food and Drug Administration to market Hextend,(R) BioTime's physiologically
balanced blood plasma volume expander, for the treatment of hypovolemia.
Hypovolemia is a condition often associated with blood loss during surgery or
from injury. Hextend maintains circulatory system fluid volume and oncotic
pressure and keeps vital organs perfused during surgery. Hextend is the only
blood plasma volume expander that contains hetastarch, buffer, multiple
electrolytes, and glucose.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
BIOTIME, INC.
/s/Paul Segall
Date: April 5, 1999 By _______________________________________
Paul E. Segall,
Chairman and Chief Executive Officer
